In addition to assisting biopharma companies unlock the potential of their own pipelines, BullFrog AI has exclusive, worldwide license agreements with major U.S. biomedical institutions to advance promising drug candidates
Repurposed small molecule for cancer therapy
Our most advanced drug asset is a repurposed small molecule therapeutic that has been formulated to improve bioavailability and increase the likelihood of demonstrating efficacy. Preclinical animal data demonstrate the potential of this drug to treat a variety of cancers and safety has been assessed in Phase I clinical trials. The company will target glioblastoma as an initial indication other undisclosed indications.
Novel mebendazole prodrug for cancer therapy
BF-223 is a novel mebendazole prodrug that has been shown in animal studies to possess significantly improved oral bioavailability compared to mebendazole, enhancing its potential utility as a therapeutic agent. The US patent for this invention was recently issued, providing strong protection for BF-223, and BullFrog AI is conducting preclinical studies in preparation for clinical development for glioblastoma and additional oncology indications.
